China-based Genuine Biotech Limited has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, according to the bourse’s website. Key details such as the unit price and offering size have not yet been disclosed.
Company Profile
Genuine Biotech is focused on the development, manufacturing, and commercialization of novel drugs targeting viral infections, tumors, and cardiovascular diseases. The company’s pipeline includes azvudine, a Category 1.1 drug conditionally approved in China for the treatment of adult HIV-1-infected patients (July 2021) and COVID-19 patients (July 2022). Azvudine is noted for its broad-spectrum anti-tumor activity and is the only nucleoside-based anti-tumor drug with a dual mechanism and high selectivity in the past 30 years.
Pipeline Highlights
- Azvudine: Approved for HIV-1 and COVID-19, with potential anti-tumor applications.
- ZS-1003: An investigational drug based on Genuine Biotech’s TOPO1 inhibitor platform with a non-camptothecin nucleus structure, showing broad-spectrum anti-tumor activity.-Fineline Info & Tech
